| abstract |
REFERRING TO A COMPOUND DERIVED FROM ISOXAZOLIDINE OF FORMULA (I), WHERE m IS 0, 1, 2 OR 3; R1 IS -OH, -OC (O) R6, -OC (O) N (R6) (R7) O -N (R6) (R7); R2 IS -OH, -N (R8) (R9), -N (R) C (O) R10, AMONG OTHERS; R3 IS ALKYL, HALIDE, AMINO, AMONG OTHERS; R4 IS ALKYL, HALIDE, AMIDO, AMONG OTHERS; R5 IS -OH O -N (R17) (R18); R6 AND R7 ARE H, ALKYL, ARALKYL, AMONG OTHERS; R8 AND R9 ARE H, ALKYL, ARALKYL, AMONG OTHERS; R10 IS ALKYL, HALOALKYL O - [C (R15) (R16)] or -COOR; R, R15 AND R16 ARE H OR ALKYL; R17 AND R18 ARE H, ALKYL, ARALKYL, AMONG OTHERS; R22 IS HALIDE OR ALKYL; R23 IS ALKYL, HYDROXYALKYL, HALOALKYL, AMONG OTHERS; R24 IS RENTAL, HALOALKYL, AMONG OTHERS; R25 IS ALKYL, HYDROXYALKYL, ALCOXYALKYL, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS ARE INHIBITORS OF Bcl PROTEINS AND ARE USEFUL IN THE TREATMENT OF CELLULAR HYPERPROLIFERATION DISORDERS SUCH AS CANCER |